Biomarker Research Services Market by Service Type (Discovery Services, Development Services, Analytical Services), Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Diabetes), End-User Industry (Pharmaceutical & Biotechnology, Contract Research Organizations, Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories), and Technology (Genomic Biomarkers, Proteomic Biomarkers, Imaging Biomarkers, Metabolomic Biomarkers); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Biomarker Research Services Market was valued at USD 5.6 billion in 2023 and will surpass USD 19.8 billion by 2030; growing at a CAGR of 20.0% during 2024 - 2030.

The biomarker research services market is witnessing rapid growth, driven by advancements in personalized medicine, precision therapies, and novel drug development. Biomarkers are vital for understanding diseases at a molecular level, aiding in diagnostics, prognostics, and therapeutic decision-making. With increasing demand for innovative therapies and early disease detection, the market has attracted significant investment in genomic, proteomic, and imaging technologies. Companies in the biomarker research space are focusing on improving their service offerings, from discovery to validation, to meet the needs of pharmaceutical, biotechnology, and clinical research sectors. The market's evolution is also fueled by the continuous improvement in biomarker technologies, such as genomic and proteomic tools, enabling faster and more accurate results.

Discovery Services Are Largest Owing to Demand for Early Disease Detection

Among the various service types in biomarker research, discovery services hold the largest share. This segment is integral to identifying novel biomarkers in various disease areas, with oncology being the leading therapeutic field. Discovery services involve the use of high-throughput technologies, such as genomic sequencing, mass spectrometry, and bioinformatics, to uncover new biomarkers that can be used in diagnostics and therapeutic strategies. The rising prevalence of cancer and other chronic diseases has led to increased investments in early-stage biomarker discovery, driving the growth of this segment. Furthermore, the focus on personalized medicine has heightened the demand for new biomarkers that can predict treatment responses and monitor disease progression.

Biomarker Research Services Market Size

Oncology Application Is Largest Due to High Prevalence of Cancer

In the application segment, oncology is the largest and most significant area. Cancer biomarkers are used for early detection, prognosis, and monitoring the efficacy of therapies, making oncology the dominant therapeutic application. The growing incidence of cancer worldwide, along with the increasing emphasis on personalized cancer treatments, has significantly contributed to the rise in biomarker research in oncology. Key applications include the identification of genetic mutations, protein markers, and other molecular changes specific to different types of cancer, which help in determining the most effective treatment plans for patients. The oncology biomarker market is expected to continue growing due to advancements in next-generation sequencing (NGS) and liquid biopsy technologies.

Pharmaceutical & Biotechnology Industry Is Largest End-User

The pharmaceutical and biotechnology sector represents the largest end-user industry for biomarker research services. This industry’s demand for biomarker services is driven by the need for more targeted and efficient drug development processes. Pharmaceutical companies use biomarkers to identify drug targets, stratify patient populations in clinical trials, and assess drug efficacy and safety. With the rise of biologics and precision medicine, pharmaceutical and biotech companies are increasingly incorporating biomarkers into their drug development pipelines to streamline the R&D process. This demand is expected to grow as personalized medicine becomes more mainstream, especially in fields such as oncology and immunology.

Genomic Biomarkers Are Fastest Growing Technology

Among the various technologies used in biomarker research, genomic biomarkers are the fastest growing. The development of genomic sequencing technologies, such as next-generation sequencing (NGS), has accelerated the identification and validation of genetic biomarkers that can be used for early disease detection, diagnosis, and treatment monitoring. Genomic biomarkers are particularly important in cancer, where genetic mutations and alterations in DNA are often used to guide therapeutic decisions. As genomic technologies continue to improve in terms of speed, accuracy, and affordability, the demand for genomic biomarker research is poised to increase, fueling growth in this technology segment.

Regional Insights: North America Leads the Biomarker Research Market

North America holds the largest share of the biomarker research services market, driven by high investments in research and development, the presence of leading pharmaceutical companies, and advanced healthcare infrastructure. The U.S. is the hub of biomarker research, with major pharmaceutical companies, academic institutions, and CROs focusing on developing novel biomarkers for various diseases. Additionally, the U.S. FDA’s increasing focus on personalized medicine and biomarker-based drug approvals has further spurred the growth of biomarker research services. As the demand for personalized treatments and early diagnostics continues to rise, North America is expected to maintain its dominant position in the market.

 Biomarker Research Services Market Size by Region 2030

Competitive Landscape: Key Players and Market Dynamics

Leading companies in the biomarker research services market include Thermo Fisher Scientific, Illumina, Labcorp Drug Development, Q2 Solutions, and Charles River Laboratories. These companies are focusing on expanding their biomarker service offerings through acquisitions, partnerships, and technological advancements. For instance, Thermo Fisher has strengthened its position in the market through strategic acquisitions, while Illumina is continuously improving its genomic technologies for biomarker discovery. The competitive landscape is also shaped by the increasing trend of partnerships between biotechnology firms and research organizations to co-develop biomarkers for specific therapeutic areas. Companies that integrate cutting-edge technologies such as genomic sequencing, proteomics, and AI into their biomarker services are likely to lead the market in the coming years. As demand for personalized medicine continues to surge, these players are focusing on enhancing their research capabilities to stay competitive in the evolving market.

In conclusion, the biomarker research services market is expanding rapidly, driven by the increasing demand for precision medicine, personalized treatments, and early disease detection. With oncology leading the charge in applications, discovery services playing a significant role in identifying novel biomarkers, and genomic biomarkers emerging as the fastest-growing technology, the market holds immense potential. North America is expected to remain the largest region, while companies like Thermo Fisher Scientific, Illumina, and Labcorp continue to dominate the competitive landscape. As the market evolves, the adoption of new technologies and the focus on targeted therapies will continue to shape the future of biomarker research services.

Recent Developments:

  • Thermo Fisher Scientific Acquires PPD: Thermo Fisher announced the acquisition of PPD, a leading contract research organization, to expand its biomarker discovery and drug development services. This acquisition strengthens its position in the biomarker research market.
  • Illumina Partners with GlaxoSmithKline: Illumina entered into a partnership with GlaxoSmithKline to advance biomarker-driven drug development, focusing on genomics-based therapies for various diseases.
  • Merck Expands Biomarker Research with New Technologies: Merck announced the development of new tools and technologies for enhanced biomarker identification and validation, particularly in oncology and immunotherapy applications.
  • Bio-Rad Launches New Proteomic Biomarker Solutions: Bio-Rad Laboratories introduced new proteomic biomarker services aimed at improving diagnostic accuracy and therapeutic targeting for diseases like cancer and diabetes.
  • Agilent Technologies Expands Clinical Biomarker Portfolio: Agilent Technologies launched a new suite of clinical biomarker solutions, enhancing its capabilities in genomics and proteomics for precision medicine and clinical trials in oncology and infectious diseases.

List of Leading Companies:

  • Thermo Fisher Scientific Inc.
  • Covance Inc. (Labcorp Drug Development)
  • Charles River Laboratories
  • Labcorp
  • Q2 Solutions
  • WuXi AppTec
  • Eurofins Scientific
  • Merck Group
  • Bio-Rad Laboratories
  • PerkinElmer
  • Illumina Inc.
  • Agilent Technologies
  • Medidata Solutions
  • Thermo Fisher Scientific
  • BIOCRATES Life Sciences AG

Report Scope:

Report Features

Description

Market Size (2023)

USD 5.6 Billion

Forecasted Value (2030)

USD 19.8 Billion

CAGR (2024 – 2030)

20.0%

Base Year for Estimation

2023

Historic Year

2022

Forecast Period

2024 – 2030

Report Coverage

Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments

Segments Covered

Biomarker Research Services Market by Service Type (Discovery Services, Development Services, Analytical Services), Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Diabetes), End-User Industry (Pharmaceutical & Biotechnology, Contract Research Organizations, Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories), and Technology (Genomic Biomarkers, Proteomic Biomarkers, Imaging Biomarkers, Metabolomic Biomarkers)

Regional Analysis

North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa)

Major Companies

Thermo Fisher Scientific Inc., Covance Inc. (Labcorp Drug Development), Charles River Laboratories, Labcorp, Q2 Solutions, WuXi AppTec, Eurofins Scientific, Merck Group, Bio-Rad Laboratories, PerkinElmer, Illumina Inc., Agilent Technologies, Medidata Solutions, Thermo Fisher Scientific, BIOCRATES Life Sciences AG

Customization Scope

Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements

1. Introduction

   1.1. Market Definition

   1.2. Scope of the Study

   1.3. Research Assumptions

   1.4. Study Limitations

2. Research Methodology

   2.1. Research Approach

      2.1.1. Top-Down Method

      2.1.2. Bottom-Up Method

      2.1.3. Factor Impact Analysis

  2.2. Insights & Data Collection Process

      2.2.1. Secondary Research

      2.2.2. Primary Research

   2.3. Data Mining Process

      2.3.1. Data Analysis

      2.3.2. Data Validation and Revalidation

      2.3.3. Data Triangulation

3. Executive Summary

   3.1. Major Markets & Segments

   3.2. Highest Growing Regions and Respective Countries

   3.3. Impact of Growth Drivers & Inhibitors

   3.4. Regulatory Overview by Country

4. Biomarker Research Services Market, by Service Type (Market Size & Forecast: USD Million, 2022 – 2030)

   4.1. Discovery Services

   4.2. Development Services

   4.3. Analytical Services

   4.4. Others

5. Biomarker Research Services Market, by Application (Market Size & Forecast: USD Million, 2022 – 2030)

   5.1. Oncology

   5.2. Cardiovascular Diseases

   5.3. Neurological Disorders

   5.4. Infectious Diseases

   5.5. Diabetes

   5.6. Others

6. Biomarker Research Services Market, by End-User Industry (Market Size & Forecast: USD Million, 2022 – 2030)

   6.1. Pharmaceutical & Biotechnology

   6.2. Contract Research Organizations (CROs)

   6.3. Academic & Research Institutions

   6.4. Hospitals & Clinics

   6.5. Diagnostic Laboratories

   6.6. Others

7. Biomarker Research Services Market, by Technology (Market Size & Forecast: USD Million, 2022 – 2030)

   7.1. Genomic Biomarkers

   7.2. Proteomic Biomarkers

   7.3. Imaging Biomarkers

   7.4. Metabolomic Biomarkers

   7.5. Others

8. Regional Analysis (Market Size & Forecast: USD Million, 2022 – 2030)

   8.1. Regional Overview

   8.2. North America

      8.2.1. Regional Trends & Growth Drivers

      8.2.2. Barriers & Challenges

      8.2.3. Opportunities

      8.2.4. Factor Impact Analysis

      8.2.5. Technology Trends

      8.2.6. North America Biomarker Research Services Market, by Service Type

      8.2.7. North America Biomarker Research Services Market, by Application

      8.2.8. North America Biomarker Research Services Market, by End-User Industry

      8.2.9. North America Biomarker Research Services Market, by Technology

      8.2.10. By Country

         8.2.10.1. US

               8.2.10.1.1. US Biomarker Research Services Market, by Service Type

               8.2.10.1.2. US Biomarker Research Services Market, by Application

               8.2.10.1.3. US Biomarker Research Services Market, by End-User Industry

               8.2.10.1.4. US Biomarker Research Services Market, by Technology

         8.2.10.2. Canada

         8.2.10.3. Mexico

    *Similar segmentation will be provided for each region and country

   8.3. Europe

   8.4. Asia-Pacific

   8.5. Latin America

   8.6. Middle East & Africa

9. Competitive Landscape

   9.1. Overview of the Key Players

   9.2. Competitive Ecosystem

      9.2.1. Level of Fragmentation

      9.2.2. Market Consolidation

      9.2.3. Product Innovation

   9.3. Company Share Analysis

   9.4. Company Benchmarking Matrix

      9.4.1. Strategic Overview

      9.4.2. Product Innovations

   9.5. Start-up Ecosystem

   9.6. Strategic Competitive Insights/ Customer Imperatives

   9.7. ESG Matrix/ Sustainability Matrix

   9.8. Manufacturing Network

      9.8.1. Locations

      9.8.2. Supply Chain and Logistics

      9.8.3. Product Flexibility/Customization

      9.8.4. Digital Transformation and Connectivity

      9.8.5. Environmental and Regulatory Compliance

   9.9. Technology Readiness Level Matrix

   9.10. Technology Maturity Curve

   9.11. Buying Criteria

10. Company Profiles

   10.1. Thermo Fisher Scientific Inc.

      10.1.1. Company Overview

      10.1.2. Company Financials

      10.1.3. Product/Service Portfolio

      10.1.4. Recent Developments

      10.1.5. IMR Analysis

    *Similar information will be provided for other companies 

   10.2. Covance Inc. (Labcorp Drug Development)

   10.3. Charles River Laboratories

   10.4. Labcorp

   10.5. Q2 Solutions

   10.6. WuXi AppTec

   10.7. Eurofins Scientific

   10.8. Merck Group

   10.9. Bio-Rad Laboratories

   10.10. PerkinElmer

   10.11. Illumina Inc.

   10.12. Agilent Technologies

   10.13. Medidata Solutions

   10.14. Thermo Fisher Scientific

   10.15. BIOCRATES Life Sciences AG

11. Appendix

A comprehensive market research approach was employed to gather and analyze data on the Biomarker Research Services Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Biomarker Research Services Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.

Research Approach - Biomarker Research Services Market

Secondary Research

Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.

Primary Research

Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the Biomarker Research Services ecosystem. The primary research objectives included:

  • Validating findings and assumptions derived from secondary research
  • Gathering qualitative and quantitative data on market trends, drivers, and challenges
  • Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
  • Assessing the supply-side landscape, including technological advancements and recent developments

Market Size Assessment

A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Biomarker Research Services Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:

  1. Identification of key industry players and relevant revenues through extensive secondary research
  2. Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
  3. Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources

Bottom Up and Top Down - Biomarker Research Services Market

Data Triangulation

To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.

NA

Please state your requirements.


I have read the Terms & Conditions and Privacy Policy. I agree to its terms.

Report Buying Options